[Inhibition of the renin angiotensin system in pregnancy and risk of fetal malformations].
Lonati
C
C
Unità Operativa di Medicina Generale e Centro Ipertensione Arteriosa, Ospedale San Giuseppe, Università degli Studi, Milano. lonati.chiara@libero.it
Morganti
A
A
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects*; D002585:Cesarean Section; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005260:Female; D005313:Fetal Death / Q000139:chemically induced; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000188:drug therapy*; D007231:Infant, Newborn; D019808:Losartan / Q000009:adverse effects; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D012084:Renin-Angiotensin System / Q000187:drug effects*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D019808:Losartan